Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054178 · ClinicalTrials.gov registry record · Phase 2
Identification of Nerves Using Fluorescein Sodium
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT06054178: Completed Phase 2 study, sponsored by Stanford University.
NCT06054178 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06054178, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to see if there is benefit in using an IV contrast (sodium fluorescein) to identify nerves during head and neck surgery.
Primary Outcome
Surgeon assessment of fluorescence correlation with electrostimulation using a Likert-style rating from 1-4 where 1=No correlation; 2=Some correlation; 3=Good correlation; 4=Excellent correlation
Interventions
- DRUG Fluorescein Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-11-07 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 2 |
What the finished NCT06054178 record still lists
NCT06054178 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Fluorescein Sodium is the first listed.
NCT06054178 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06054178 about?
NCT06054178 is a clinical study titled "Identification of Nerves Using Fluorescein Sodium". The purpose of this study is to see if there is benefit in using an IV contrast (sodium fluorescein) to identify nerves during head and neck surgery.
What is the current status of trial NCT06054178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2024-11-07. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT06054178?
The interventions under investigation include: Fluorescein Sodium (DRUG).
Who is sponsoring clinical trial NCT06054178?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06054178's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI